Trisomy of Chromosome 21 Diagnosis by High Output Sequencing
Demonstrate that the High output shotgun sequencing of the foetal DNA in the maternal blood could allow a complete discrimination between the mothers of a trisomic fetus 21 or a DISOMIQUE foetus 21 from the first quarter of the pregnancy, and so to obtain a reliable alternative in invasive procedure.
Justification of the research :
The trisomy 21 is the most frequent cause of handicap of genetic origin with an incidence of 1.3/1 000 births which increases with the maternal age. Several strategies of antenatal screening were developed. The High Authority of Health recently recommended to propose to the pregnant women a 1st trimester combined screening, realized between 11+0 and 13+6 weeks of amenorrhoea, associating measure of the NUCALE translucency and dosage in maternal serum : PAPP-A (Pregnancy Associated Plasma Protein A) and βhCG (free β human Chorionic 1st trimester Gonadotrophin). However, the sensibility of these screening tests is about 80 % for 5 % of positive false. The diagnosis of aneuploidy is then established on a population classified at high risk, by a foetal karyotype (requiring an invasive procedure : biopsy of trophoblast or amniocentesis). A positive screening increase maternal and medical anxiety. Furthermore, the inappropriate combination of the tests is at the origin of numerous useless invasive procedures (national rate of amniocentesis of 11 %), at risk of foetal losses (0,5 in 1 %). This inflation of invasive procedures leads to so many losses of not affected children as trisomic children and to a badly known maternal morbidity.
Several studies showed that 10 % of the free DNA found from the first quarter of the pregnancy in the maternal plasma is of foetal origin and that this DNA is specific of the foetal nuclear DNA of the current pregnancy. This opened the way of a possible not invasive antenatal diagnosis of the foetal aneuploidy which collided during the last 10 years with the performances limited by the isolation and by the sequencing of the foetal DNA in the maternal plasma. A new technique of analysis by broadband sequencing of the DNA circulating in the maternal blood for the diagnosis of the most frequent aneuploid the trisomy 21 of which was brought back(reported). The High-output shotgun sequencing of all the DNA circulating in the maternal blood, then the reading and the identification of all the chromosome sequences allows to analyze the quantity of DNA resulting from the supernumerary chromosome, without necessity of differentiating maternal and foetal DNA. On the basis of very recent works 10, this excess of sequences resulting specifically from the chromosome 21 foetal supernumerary allows a discrimination completes between trisomy 21 and disomy 21. However, this study analyzed only 9 cases of trisomy 21 and the sampling of maternal blood were realized after the amniocentesis or the choriocenteses, what could artificially have increased the quantity of circulating foetal DNA.
Demonstrate that the High output shotgun sequencing of the foetal DNA in the maternal blood could allow a complete discrimination between the mothers of a trisomic fetus 21 or a DISOMIQUE fetus 21 from the first quarter of the pregnancy, and so to obtain a reliable alternative in invasive procedure.
Method Two public centres of antenatal screening were established to answer specifically the recommendations of the High Authority of Health and have the capacity to make 20 000 acts of screenings a year. All the women presenting a high risk (> 1/250) of aneuploidy and the candidates to an invasive procedure, will see suggesting participating in the study. The included patients will have a maternal blood sample before the invasive test. This taking will be put in on hold in-80°C after centrifugation following the recommended protocol. At the end of inclusion, the technic of analysis of the circulating DNA will be realized then blind by the laboratory on all the diagnosed cases (by usual invasive examination, or at the conclusion of the pregnancy) of trisomy 21 and on control representative of all the spectre of the levels of risk. A study of reproducibility of the quantification of the DNA of the chromosome 21 will be realized.
Number of subjects:
we plan to include 75 cases of trisomy 21 and 150 control cases with normal karyotype, what allows to detect a 99,9 % sensibility and a 99,99 % specificity with a power of at least 95 %.
Duration of the study:
these objectives are practicable in two years on the basis of the number of invasive takings realized in both center and an already realized study
Ethical Aspects: research on data and biological collection. No individual medical decision will be taken according to the estimated test.
this new technique, if it is generalizable, would allow to limit the number of procedures of invasive diagnosis (amniocentesis and choriocentesis) which contain a significant risk of grave maternal and fetal complications, while optimizing the capacities of this screening.
Observational Model: Case Control, Time Perspective: Prospective
Trisomy of Chromosome 21
Necker Enfants Malades
Assistance Publique - Hôpitaux de Paris
Results (where available)
- Source: http://clinicaltrials.gov/show/NCT01118507
- Information obtained from ClinicalTrials.gov on July 15, 2010
The overall significance of this study is to develop a laboratory developed test (LDT) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chr...
Primary sclerosing cholangitis (PSC) is a chronic inflammatory condition of the bile ducts of unknown etiology. It is characterized by diffuse inflammation and stricturing of the entire bi...
Our vision, that of the researchers at the University of Texas Health Science Center at San Antonio, is that every person with a chromosome 18 abnormality will have an autonomous and healt...
Failure to thrive and difficulty gaining weight is a sign of uncompensated congestive heart failure (CHF). Infants with Trisomy 21 and complete atrioventricular canal defects (CAVC) frequ...
This study will explore the efficacy and safety of a regimen of ON 01910.Na as a 48-hour continuous intravenous infusion once a week for 3 weeks of a 4-week cycle in MDS patients with Tris...
Teratomas are very rare intracranial tumors and cytogenetic information on this group remains rare. We report a case of a mature teratoma with abnormal +21 trisomy in tumor karyotype ocurring in a non...
Using quinacrine fluorescence and Giemsa banding techniques we have identified an extra chromosome 22 in three non-mongoloid children with similar phenotypes and 47 chromosomes. In one of the children...
Whether chromosome abnormalities observed in tumor cells may in some cases reflect low-grade somatic mosaicism for anomalies present already at zygote formation, rather than acquired somatic mutations...
Background and Aim: Trisomy 13 (Patau syndrome) was first described by Patau et al in 1960. It is characterized by serious head, facial, and extremity anomalies, congenital heart defects, and mental a...
Subtelomeric deletions and duplications may cause syndromic disorders that include features of immunodeficiency. To date, no phenotype of immunological pathology has been linked to partial trisomy 19....
Medical and Biotech [MESH] Definitions
The chromosomal constitution of cells which deviate from the normal by the addition or subtraction of CHROMOSOMES, chromosome pairs, or chromosome fragments. In a normally diploid cell (DIPLOIDY) the loss of a chromosome pair is termed nullisomy (symbol: 2N-2), the loss of a single chromosome is MONOSOMY (symbol: 2N-1), the addition of a chromosome pair is tetrasomy (symbol: 2N+2), the addition of a single chromosome is TRISOMY (symbol: 2N+1).
Congenital conditions of atypical sexual development associated with abnormal sex chromosome constitutions including MONOSOMY; TRISOMY; and MOSAICISM.
The possession of a third chromosome of any one type in an otherwise diploid cell.
The 46,XX gonadal dysgenesis may be sporadic or familial. Familial XX gonadal dysgenesis is transmitted as an autosomal recessive trait and its locus was mapped to chromosome 2. Mutation in the gene for the FSH receptor (RECEPTORS, FSH) was detected. Sporadic XX gonadal dysgenesis is heterogeneous and has been associated with trisomy-13 and trisomy-18. These phenotypic females are characterized by a normal stature, sexual infantilism, bilateral streak gonads, amenorrhea, elevated plasma LUTEINIZING HORMONE and FSH concentration. The syndrome is sometimes called "pure gonadal dysgenesis," but this designation may also refer to gonadal dysgenesis with a 46,XY karyotype (GONADAL DYSGENESIS, 46,XY).
Clinical conditions caused by an abnormal sex chromosome constitution (SEX CHROMOSOME ABERRATIONS) in which there is extra or missing sex chromosome material (either a whole chromosome or a chromosome segment).